GAMMAGARD S/D

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
GAMMAGARD S/D
Generic name
IMMUNE GLOBULIN INTRAVENOUS (HUMAN)
Manufacturer
Takeda Pharmaceuticals America, Inc.
Product type
PLASMA DERIVATIVE
SPL set ID
bf8df9fd-bfdd-47c2-84d2-d91e50947bf6
SPL ID
123bfa78-6fbe-41c7-8e01-c885e58c1437
Version
12
Effective date
2025-11-25
Source export date
2026-11-13
Source partition
7
Source file
https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/875ce92e4370b2000cf566c8a9c0e4d02cceccd3a3b18a8b0b87928b28506f0b/drug-label-0007-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:35:17

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Boxed warning sections page 1 of 1 · 1 matching rows.

boxed warning

WARNING: THROMBOSIS, RENAL DYSFUNCTION, and ACUTE RENAL FAILURE ■ Thrombosis may occur with immune globulin products, including GAMMAGARD S/D. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors [see Warnings and Precautions (5.3) , Patient Counseling Information (17) ]. ● Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients who receive immune globulin intravenous (IGIV) products, including GAMMAGARD S/D. Patients predisposed to renal dysfunction include those with any degree of pre-existing renal insufficiency, diabetes mellitus, age above 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV product containing sucrose. GAMMAGARD S/D does not contain sucrose. (5.2) ● For patients at risk of thrombosis, administer GAMMAGARD S/D at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity [see Dosage and Administration (2.3) and Warnings and Precautions (5.3) ]. WARNING: THROMBOSIS, RENAL DYSFUNCTION, and ACUTE RENAL FAILURE See full prescribing information for complete boxed warning. Thrombosis may occur with immune globulin products, including GAMMAGARD S/D. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity and cardiovascular risk factors. ( 5.3 ) Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients with immune globulin intravenous (IGIV) products, including GAMMAGARD S/D. Renal dysfunction and acute failure occur more commonly with IGIV products containing sucrose. GAMMAGARD S/D does not contain sucrose. ( 5.2 ) For patients at risk of thrombosis, administer GAMMAGARD S/D at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity. ( 5.3 )

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS IgA-deficient patients with antibodies to IgA are at greater risk of severe hypersensitivity reactions and anaphylactic reactions. ( 5.1 ) Monitor renal function, including blood urea nitrogen, serum creatinine, and urine output in patients at risk of acute renal failure. ( 5.2 ) Thrombosis may occur. Monitor for signs and symptoms of thrombosis and assess blood viscosity for those at risk for hyperviscosity. ( 5.3 ) Aseptic Meningitis Syndrome (AMS) has been reported ( 5.4 ) Hemolytic anemia can develop. Monitor patients for clinical signs and symptoms of hemolysis and hemolytic anemia. ( 5.5 ) Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury, TRALI). ( 5.6 ) GAMMAGARD S/D is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. ( 5.7 ) Hyperproteinemia, increased serum viscosity, and alterations in serum sodium levels may occur. ( 5.8 ) 5.1 Hypersensitivity Severe hypersensitivity reactions and anaphylactic reactions with a fall in blood pressure have occurred in patients receiving GAMMAGARD S/D, including patients who tolerated previous treatments with GAMMAGARD S/D, even though it contains low levels of IgA. If hypersensitivity reaction develops, discontinue GAMMAGARD S/D infusion immediately and institute appropriate treatment. This product has an IgA concentration less than 1 µg/mL. Preparations depleted of IgA (0.4 to 2.9 µg/mL) were shown to be better tolerated by a limited number of patients who reacted to IGIV preparations with higher IgA concentrations. However, the concentration of IgA that will not provoke a reaction is not known, and therefore all IGIV preparations carry the risk of inducing an anaphylactic reaction to IgA. In such instances, a risk of anaphylaxis may exist despite the fact that GAMMAGARD S/D, IgA < 1 µg/mL, contains < 1 µg/mL IgA. 5.2 Renal Dysfunction/Failure Acute renal failure has been reported in association with GAMMAGARD S/D. Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis and death have been reported in patients receiving IGIV, particularly those products containing sucrose. 10 GAMMAGARD S/D does not contain sucrose. Ensure that patients are not volume depleted prior to the initiation of the infusion of GAMMAGARD S/D. In patients who are at risk of developing renal dysfunction, because of pre-existing renal insufficiency or predisposition to acute renal failure (such as diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs, etc.), administer GAMMAGARD S/D at an infusion rate less than 4 mL/kg/hour (< 3.3 mg IG/kg/min) for a 5% solution or at a rate less than 2 mL/kg/hour (< 3.3 mg IG/kg/min) for a 10 % solution [see Dosage and Administration (2) ]. Monitor renal function and urine output in patients judged to be at increased risk for developing acute renal failure. Assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion of GAMMAGARD S/D and again at appropriate intervals thereafter. If renal function deteriorates, consider discontinuation of GAMMAGARD S/D. 5.3 Thrombosis Thrombosis may occur following treatment with immune globulin products, including GAMMAGARD S/D. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies. For patients at risk of thrombosis, administer GAMMAGARD S/D at the minimum dose and infusion rate practicable . Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity [see Boxed Warning , Dosage and Administration (2.3) , Patient Counseling Information (17) ]. 5.4 Aseptic Meningitis Syndrome (AMS) AMS has been reported to occur in association with immune globulin therapy, including GAMMAGARD S/D. AMS may occur more frequently in female patients. Discontinuation of immune globulin treatment has resulted in remission of AMS within several days without sequelae. The syndrome of AMS usually begins within several hours to two days following immune globulin treatment. AMS is characterized by the following symptoms and signs: severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea, and vomiting. Cerebrospinal fluid (CSF) studies are frequently positive with pleocytosis up to several thousand cells per cubic mm, predominantly from the granulocytic series, and with elevated protein levels up to several hundred mg/dL, but negative culture results. Conduct a thorough neurological examination on patients exhibiting such symptoms and signs, including CSF studies, to rule out other causes of meningitis. 5.5 Hemolysis Hemolytic anemia can develop subsequent to IGIV therapy, including GAMMAGARD S/D 11 [see Adverse Reactions (6.2) ]. GAMMAGARD S/D contains blood group antibodies which may act as hemolysins and induce in vivo coating of red blood cells (RBC) with immunoglobulin, causing a positive direct antiglobulin reaction and, rarely, hemolysis. Acute intravascular hemolysis has been reported, and delayed hemolytic anemia can develop subsequent to IGIV therapy due to enhanced RBC sequestration [see Adverse Reactions (6.2) ]. Monitor patients for clinical signs and symptoms of hemolysis. If signs or symptoms of hemolysis are present after GAMMAGARD S/D infusion, perform appropriate confirmatory laboratory testing. 5.6 Transfusion-Related Acute Lung Injury (TRALI) Non-cardiogenic pulmonary edema (TRALI) has been reported in patients following the administration of immunoglobulin products, including GAMMAGARD S/D therapy [see Adverse Reactions (6.2) ]. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever. Symptoms typically occur within 1 to 6 hours after treatment. Monitor patients for pulmonary adverse reactions . If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil and anti-HLA antibodies in both the product and patient serum. TRALI may be managed using oxygen therapy with adequate ventilatory support. 5.7 Transmissible Infectious Agents Because GAMMAGARD S/D is made from human blood and may carry a risk of transmitting infectious agents, e.g., viruses the variant Creutzfeldt-Jakob disease (vCJD) agent and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens. All infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) (in the U.S.) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . The physician should discuss the risks and benefits of this product with the patient. 5.8 Hyperproteinemia, Increased Serum Viscosity, and Alterations in Serum Sodium Levels Hyperproteinemia and increased serum viscosity may occur in patients receiving GAMMAGARD S/D. Alterations in serum sodium levels, such as hypernatremia acutely, or pseudohyponatremia after equilibration of the sodium, may occur with the administration of GAMMAGARD S/D. The amount of sodium in the product may add materially to the recommended daily allowance of dietary sodium for patients on a low sodium diet. In these patients, calculate the amount of sodium from the product and use it when determining dietary sodium intake. GAMMAGARD S/D contains approximately 0.85% NaCl or approximately 3340 mg sodium/liter at a 5% concentration. A 70 kg patient receiving 1g/kg (1.4 L) of the product would receive 4676 mg of sodium. 5.9 Monitoring: Laboratory Tests Monitor renal function and urine output in patients at increased risk of developing acute renal failure. Assess renal function, including measurement of BUN and serum creatinine, before the initial infusion of GAMMAGARD S/D and at appropriate intervals thereafter. 10 Assess baseline blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies because of the potentially increased risk of thrombosis. If signs or symptoms of hemolysis are present after an infusion of GAMMAGARD S/D, perform appropriate laboratory testing for confirmation. If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies and anti-HLA antibodies in both the product and patient's serum. 5.10 Interference with Laboratory Tests After infusion of IgG, the transitory rise of the various passively transferred antibodies in the patient's blood may yield false positive serological testing results, with the potential for misleading interpretation. Passive transmission of antibodies to erythrocyte antigens (e.g., A, B, and D) may cause a positive direct or indirect antiglobulin (Coombs') test. Administration of GAMMAGARD S/D can lead to false positive readings in assays that depend on detection of beta-D-glucans for diagnosis of fungal infections; this may persist during the weeks following infusion of the product.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 2 · 6 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most common adverse reactions reported in ≥ 5% of clinical trial subjects occurring during or within 48 hours of an infusion were headache, nausea, chills, asthenia (fatigue), pyrexia, upper abdominal pain, diarrhea, back pain, hyperhidrosis, and flushing. There were no serious adverse events that were attributed to GAMMAGARD S/D in the clinical trials. In postmarketing surveillance, serious adverse reactions reported with GAMMAGARD S/D were anaphylaxis, acute renal failure, myocardial infarction, cerebral vascular accident, transient ischemic attack, deep vein thrombosis, pulmonary embolism, aseptic meningitis, acute hemolysis, and TRALI. The most common adverse reactions observed in ≥ 5% of patients during the clinical trials were headache, nausea, chills, fatigue, pyrexia, upper abdominal pain, diarrhea, back pain, infusion site pain, hyperhidrosis and flushing. ( 6.1 ) The most serious adverse reactions reported postmarketing include renal failure, thrombotic events (myocardial infarction, cerebrovascular accidents, and pulmonary embolism), anaphylactic shock, aseptic meningitis and hemolysis. ( 6.2 ) To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Primary Immunodeficiency (PI) In 17 patients receiving GAMMAGARD (5% solution) for 56 to 77 months, 12 (71%) were adults, and 5 (29%) were children (16 years or younger). 3 Adverse reactions are those adverse events (AEs) that were deemed by the investigators as causally related to the infusion of GAMMAGARD. Twenty-one adverse reactions occurred in 6 of the 17 subjects with a total of 341 infusions (6%). There was one death in a woman from a cerebral vascular hemorrhage secondary to thrombocytopenia that was considered unrelated to study product. Of the 5 subjects who received an infusion with 600 mg/kg at a rate of 0.3 g/kg/hour, two subjects experienced adverse reactions, with an adverse reaction rate of 40%. The adverse reactions that occurred in ≥ 5% of subjects during or within 48 hours of infusion are listed in Table 2. Table 2 Adverse Reactions that Occurred in ≥ 5% of Subjects During or Within 48 Hours of Infusion Adverse Reaction By Subjects (%) Total number of subjects: 17 By Infusions (%) Total number of infusions: 341 Headache 3 (17.6) 3 (0.9) Chills 2 (11.8) 6 (1.8) Backache 2 (11.8) 2 (0.6) Emesis 1 (5.9) 1 (0.3) Flushing 1 (5.9) 1 (0.3) Fatigue 1 (5.9) 4 (1.2) Dizziness 1 (5.9) 1 (0.3) In a double-blind, crossover study, 36 subjects with PI were treated for 6 months with GAMMAGARD S/D and 6 months with Gamimune N. One hundred AEs were considered to be possibly or probably related to treatment with GAMMAGARD S/D. Of these, 72 were mild, 24 were moderate, and 4 were severe. The numbers and percentages of AEs were similar for GAMMAGARD S/D and Gamimune N. There were no deaths during the study. The adverse reactions that occurred during GAMMAGARD S/D treatment in ≥ 5% of subjects in the study are shown in Table 3. Table 3 Adverse Reactions that Occurred in ≥ 5% of Subjects Treated with GAMMAGARD S/D Adverse Reactions By Subject (%) Total number of subjects: 36 By Infusion (%) Total number of infusions: 211 Headache 11 (30.6) 23 (10.9) Nausea 8 (22.2) 14 (6.6) Chills 7 (19.4) 14 (6.6) Fatigue 4 (11.1) 11 (5.2) Pyrexia 4 (11.1) 6 (2.8) Upper Abdominal Pain 3 (8.3) 3 (1.4) Diarrhea 3 (8.3) 3 (1.4) Back Pain 3 (8.3) 4 (1.9) Infusion Site Pain 2 (5.6) 3 (1.4) Hyperhidrosis 2 (5.6) 4 (1.9) Flushing 2 (5.6) 2 (1.0) In 10 subjects who participated in a PK crossover study of GAMMAGARD and GAMMAGARD S/D, 5 adverse reactions were reported to be associated with the total 28 infusions (17.5%). Three of the adverse reactions were associated with 10 GAMMAGARD infusions and 2 were associated with 18 GAMMAGARD S/D infusions. Two subjects withdrew from the study. One subject developed a recurrence of chronic cellulitis and was hospitalized, but the event was not considered to be related to study drug. The other subject withdrew because of moderate severe adverse reactions including chills, anxiety, and increased temperature after infusion of GAMMAGARD. Adverse reactions that occurred in the PK study and in the safety study are shown in Table 4. Table 4 Adverse Reactions that Occurred During or Within 48 Hours of an Infusion of GAMMAGARD S/D Event By Infusion (%) Total number: 394 Headache 20 (5.1) Chills 11 (2.7) Elevated Temperature 7 (1.8) Nausea 6 (1.5) Emesis 5 (1.3) Hypertension 4 (1.0) Fatigue 4 (1.0) Flushing 4 (1.0) Leg Cramps 3 (0.8) Flu-Like Symptoms 2 (0.5) Exanthema 2 (0.5) Loss of Appetite 2 (0.5) Anxiety 1 (0.3) Backache 1 (0.3) Urticaria 1 (0.3) The tolerability and viral safety of GAMMAGARD S/D were evaluated in a study of 38 subjects treated with GAMMAGARD S/D for an average of 7.7 months. Adverse reactions were reported from 20 of the 38 subjects (52.6%) in 50 of the total 394 infusions (12.7%) during or within 48 hours of an infusion. Twenty-four (48%) of the adverse reactions occurred in 3 subjects and 26 occurred in the other 35 subjects in 350 infusions. No subject withdrew during the study. Five subjects had a transient borderline elevation in liver enzyme (AST). No subject developed a positive serologic response to hepatitis C or HIV. There were no other significant laboratory abnormalities. The adverse experiences of GAMMAGARD S/D reconstituted as a 10% solution and the maximal tolerated infusion rate were examined in a post-marketing study of 27 subjects. Local pain and/or irritation occurred in 42 of the total 276 infusions (15.2%). Ninety percent of the reactions occurred when the patients received the 10% solution compared to the 5% control. These local reactions tended to be more common following hand vein infusions and their incidence may be reduced by infusions via the antecubital vein. Application of a warm compress to the infusion site alleviated local symptoms. Twenty-six subjects achieved the maximal infusion rate of 8 mL/kg/hour with the GAMMAGARD S/D reconstituted to a 10% solution. B -cell Chronic Lymphocytic Leukemia (CLL) In the study of 81 patients with B-cell CLL, the incidence of adverse reactions following GAMMAGARD infusions was approximately 1.3% compared to the rate of the placebo (normal saline) group which was 0.6%. 3 There were 23 adverse reactions associated with the 1235 infusions in the study. Sixteen of the adverse reactions occurred in the GAMMAGARD group (1.6%) and 7 in the control group (0.6%). The most common reactions were fever and chills. Sleepiness was noted during 4 infusions. One subject had a myocardial infarction which was considered to be unrelated to the GAMMAGARD. Twenty-four of the subjects did not complete all 17 infusions. Three subjects in each group died during the study, five of whom were due to infection. The other 18 subjects withdrew for reasons unrelated to the treatment. Idiopathic Thrombocytopenic Purpura (ITP) During the clinical study of GAMMAGARD for the treatment of ITP, headache occurred in 12 of 16 subjects (75%) and was the only adverse reaction reported. Of these 12 subjects, 11 had chronic ITP (9 adults, 2 children), and one child had acute ITP. Oral antihistamines and analgesics alleviated the symptoms and were used as pretreatment for those subjects requiring additional IGIV therapy. Kawasaki Syndrome In a study of 51 subjects with Kawasaki syndrome, no hypersensitivity reactions (urticaria, bronchospasm or generalized anaphylaxis) were reported in subjects receiving either a single 1g/kg dose or 400 mg/kg of GAMMAGARD for four consecutive days. Adverse reactions, including chills, flushing, cramping, headache, hypotension, nausea, rash, and wheezing, were reported with both dose regimens. These adverse reactions occurred in 7 of the 51 (13.7%) subjects associated with 7 of the total 129 (5.4%) infusions. Of the 25 subjects who received a single 1 g/kg dose, 4 subjects (16%) experienced adverse reactions. Of the 26 subjects who received 400 mg/kg/day over 4 days, 3 (11.5%) experienced adverse reactions. 6.2 Postmarketing Experience Because adverse reactions are reported voluntarily post-approval from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to product exposure. The following adverse reactions have been reported during postmarketing use of GAMMAGARD S/D (Table 5). Table 5 Adverse Reactions from Postmarketing Experience Blood and Lymphatic System Disorders Anemia, hemolysis, lymphadenopathy, thrombocytopenia Immune System Disorders Anaphylactic shock, anaphylactic/anaphylactoid reaction, hypersensitivity Psychiatric Disorders Restlessness Nervous System Disorders Aseptic meningitis, cerebrovascular accident, transient ischemic attack, seizures, dizziness, migraine, paresthesia, syncope, tremor Eye Disorders Retinal vein thrombosis, eye pain, photophobia, visual disturbance Cardiac Disorders Myocardial infarction, cyanosis, tachycardia, bradycardia Vascular Disorders Vena cava thrombosis, arterial thrombosis, deep vein thrombosis, hypotension, hypertension, pallor, thrombophlebitis Respiratory, Thoracic And Mediastinal Disorders Pulmonary embolism, pulmonary edema, bronchospasm, wheezing, cough, hyperventilation, hypoxia, throat tightness Gastrointestinal Disorders Abdominal pain, dyspepsia Hepatobiliary Disorders Non-infectious hepatitis Skin and Subcutaneous Tissue Disorders Angioedema, dermatitis, erythema, rash Musculoskeletal And Connective Tissue Disorders Arthralgia, myalgia Renal and Urinary Disorders Renal failure General Disorders And Administration-Site Conditions Infusion site reaction, asthenia, edema, rigors Investigations Positive direct Coombs test In addition to the events listed above, the following events have been identified for IGIV products in general: Renal Osmotic nephrosis Respiratory Cyanosis, apnea, acute respiratory distress syndrome (ARDS) Integumentary Bullous dermatitis, epidermolysis, erythema multiforme, Stevens-Johnson syndrome Cardiovascular Cardiac arrest, vascular collapse Neurological Coma, loss of consciousness Hematologic Pancytopenia Gastrointestinal Hepatic dysfunction

adverse reactions table

<table width="75%"><caption>Table 2 Adverse Reactions that Occurred in &#x2265; 5% of Subjects During or Within 48 Hours of Infusion</caption><col width="20%" align="left" valign="top"/><col width="40%" align="center" valign="top"/><col width="40%" align="center" valign="top"/><thead><tr><th styleCode="Lrule Rrule" align="center">Adverse Reaction</th><th styleCode="Rrule" align="center">By Subjects (%) Total number of subjects: 17</th><th styleCode="Rrule" align="center">By Infusions (%) Total number of infusions: 341</th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Headache</td><td styleCode="Rrule">3 (17.6)</td><td styleCode="Rrule">3 (0.9)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule Botrule">Chills</td><td styleCode="Rrule Botrule">2 (11.8)</td><td styleCode="Rrule Botrule">6 (1.8)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule Botrule">Backache</td><td styleCode="Rrule Botrule">2 (11.8)</td><td styleCode="Rrule Botrule">2 (0.6)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule Botrule">Emesis</td><td styleCode="Rrule Botrule">1 (5.9)</td><td styleCode="Rrule Botrule">1 (0.3)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule Botrule">Flushing</td><td styleCode="Rrule Botrule">1 (5.9)</td><td styleCode="Rrule Botrule">1 (0.3)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule Botrule">Fatigue</td><td styleCode="Rrule Botrule">1 (5.9)</td><td styleCode="Rrule Botrule">4 (1.2)</td></tr><tr><td styleCode="Lrule Rrule">Dizziness</td><td styleCode="Rrule">1 (5.9)</td><td styleCode="Rrule">1 (0.3)</td></tr></tbody></table>

adverse reactions table

<table width="75%"><caption>Table 3 Adverse Reactions that Occurred in &#x2265; 5% of Subjects Treated with GAMMAGARD S/D </caption><col width="30%" align="left" valign="top"/><col width="35%" align="center" valign="top"/><col width="35%" align="center" valign="top"/><thead><tr styleCode="Botrule"><th styleCode="Lrule Rrule" align="center" valign="middle">Adverse Reactions</th><th styleCode="Rrule" valign="middle">By Subject (%) Total number of subjects: 36</th><th styleCode="Rrule" valign="middle">By Infusion (%) Total number of infusions: 211</th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Headache</td><td styleCode="Rrule">11 (30.6)</td><td styleCode="Rrule">23 (10.9)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Nausea</td><td styleCode="Rrule">8 (22.2)</td><td styleCode="Rrule">14 (6.6)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Chills</td><td styleCode="Rrule">7 (19.4)</td><td styleCode="Rrule">14 (6.6)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Fatigue</td><td styleCode="Rrule">4 (11.1)</td><td styleCode="Rrule">11 (5.2)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Pyrexia</td><td styleCode="Rrule">4 (11.1)</td><td styleCode="Rrule">6 (2.8)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Upper Abdominal Pain</td><td styleCode="Rrule">3 (8.3)</td><td styleCode="Rrule">3 (1.4)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Diarrhea</td><td styleCode="Rrule">3 (8.3)</td><td styleCode="Rrule">3 (1.4)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Back Pain</td><td styleCode="Rrule">3 (8.3)</td><td styleCode="Rrule">4 (1.9)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Infusion Site Pain</td><td styleCode="Rrule">2 (5.6)</td><td styleCode="Rrule">3 (1.4)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Hyperhidrosis</td><td styleCode="Rrule">2 (5.6)</td><td styleCode="Rrule">4 (1.9)</td></tr><tr><td styleCode="Lrule Rrule">Flushing</td><td styleCode="Rrule">2 (5.6)</td><td styleCode="Rrule">2 (1.0)</td></tr></tbody></table>

adverse reactions table

<table width="60%"><caption>Table 4 Adverse Reactions that Occurred During or Within 48 Hours of an Infusion of GAMMAGARD S/D</caption><col width="45%" align="left" valign="top"/><col width="55%" align="center" valign="top"/><thead><tr><th styleCode="Lrule Rrule" align="center">Event</th><th styleCode="Rrule">By Infusion (%) Total number: 394</th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Headache</td><td styleCode="Rrule">20 (5.1)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Chills</td><td styleCode="Rrule">11 (2.7)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Elevated Temperature</td><td styleCode="Rrule">7 (1.8)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Nausea</td><td styleCode="Rrule">6 (1.5)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Emesis</td><td styleCode="Rrule">5 (1.3)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Hypertension</td><td styleCode="Rrule">4 (1.0)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Fatigue</td><td styleCode="Rrule">4 (1.0)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Flushing</td><td styleCode="Rrule">4 (1.0)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Leg Cramps</td><td styleCode="Rrule">3 (0.8)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Flu-Like Symptoms</td><td styleCode="Rrule">2 (0.5)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Exanthema</td><td styleCode="Rrule">2 (0.5)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Loss of Appetite</td><td styleCode="Rrule">2 (0.5)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Anxiety</td><td styleCode="Rrule">1 (0.3)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule">Backache</td><td styleCode="Rrule">1 (0.3)</td></tr><tr><td styleCode="Lrule Rrule">Urticaria</td><td styleCode="Rrule">1 (0.3)</td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.